Biotech

All Articles

Actinogen's cortisol blocker neglects period 2 anxiety research study

.Actinogen Medical's cortisol blocker has actually missed out on the major endpoint of a stage 2 stu...

Bivictrix chooses going private only technique to take ADC into medical clinic

.Antibody-drug conjugates (ADCs) have actually been at the facility of lots of a billion-dollar biob...

TPG bests up funds to $580M for investments around life sciences

.Property manager TPG, which has supported biotechs like Sionna Therapeutics as well as Santa Clam A...

Merck stops stage 3 TIGIT test in lung cancer cells for futility

.Merck &amp Co.'s TIGIT system has actually suffered one more problem. Months after shuttering a per...

After a challenging year, Exscientia folds up into Recursion

.After a year specified by pipe hairstyles, the shift of its own CEO as well as layoffs, Exscientia ...

Cullinan, after $25M deal, return bispecific to Harbour

.Cullinan Therapeutics was made an impression on sufficient along with Harbour BioMed's bispecific i...

A better look at Fierce Biotech's Tough 15

.Within this full week's episode of "The Top Pipe," our company are actually diving in to Ferocious ...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's party commemorating the commendation of Alzhei...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and retir...

Lykos will certainly ask FDA to reassess its own decision following denial of MDMA treatment for trauma

.Complying with an inadequate revealing for Lykos Therapeutics' MDMA candidate for post-traumatic st...